A new gene therapy reported in 2025 could slow the progression of Huntington's disease by what percentage?

Huntington's disease is a devastating, inherited neurodegenerative disorder that gradually erodes a person's physical and mental capabilities. Caused by a single genetic mutation, the disease leads to the production of a toxic protein that damages brain cells, resulting in uncontrolled movements, cognitive decline, and psychiatric problems. Until recently, treatments for Huntington's disease have focused solely on managing symptoms, offering little hope for slowing its relentless progression. However, a significant development in 2025 offered a groundbreaking possibility: a new gene therapy demonstrated the potential to slow the disease's advancement by an impressive 75%.

This innovative gene therapy, known as AMT-130, was developed through a collaboration between uniQure and University College London (UCL) scientists. It works by introducing new genetic material into the brain using a harmless viral vector, delivered through a one-time surgical procedure. This genetic material instructs brain cells to produce a microRNA molecule that effectively "silences" the faulty gene responsible for creating the toxic huntingtin protein. By targeting the root cause of the disease and reducing the production of this harmful protein, the therapy aims to protect neurons from further damage.

The preliminary results from a Phase I/II clinical trial of AMT-130, reported in 2025, showed that patients receiving a high dose of the therapy experienced a 75% less progression of the disease over a three-year period compared to those receiving standard care. This finding is particularly remarkable because it marks the first time a treatment has shown a statistically significant ability to slow the actual progression of Huntington's disease, rather than just alleviating its symptoms. While these early results are incredibly promising and offer long-awaited hope to individuals and families affected by this condition, researchers emphasize the need for larger studies before the treatment can be widely available.